Merck And Vertex Poised For Growth In Singapore's HCV Market As Medical Tourism Booms
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novel hepatitis C treatments from Merck and Vertex are expected to fare well in Singapore - with the proper marketing campaigns - due in part to increased medical tourism from neighboring Southeast Asian countries
You may also be interested in...
With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.
Indonesia Set For Explosion In Number Of Hepatitis C Cases
SHANGHAI - The incidence of patients with hepatitis C is set to explode in Indonesia, with an estimated 7 million citizens currently infected expected to surge to 11 million people by the year 2016, according to experts at Frost & Sullivan
HGS Submits BLA For Interferon Zalbin For Hepatitis C
If approved, the interferon could offer a dosing advantage over pegylated interferons, although safety data could mean a bumpy regulatory road ahead.